Post-resection/ ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418). Prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of active post-resection/ ablation therapy in patients with metastatic colorectal cancer.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512174-10-00

Acronym

FIRE-9 - PORT

Enrollment

507

Registered

2024-11-13

Start date

2021-11-11

Completion date

Unknown

Last updated

2025-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic colorectal cancer

Brief summary

Progression-free survival (PFS) time at the 24 months follow-up defined as time from randomization to death or evidence of disease (whatever occurs first)

Interventions

DRUGCALCIUM FOLINATE PENTAHYDRATE

DRUGDISODIUM FOLINATE

DRUGOXALIPLATIN

DRUGIRINOTECAN HYDROCHLORIDE TRIHYDRATE

DRUGFLUOROURACIL

DRUGCAPECITABINE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-free survival (PFS) time at the 24 months follow-up defined as time from randomization to death or evidence of disease (whatever occurs first)	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026